Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $10.0 million.

  • Nurix Therapeutics' Non-Current Deffered Revenue fell 6180.03% to $10.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $10.0 million, marking a year-over-year decrease of 6180.03%. This contributed to the annual value of $10.0 million for FY2025, which is 6180.03% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Non-Current Deffered Revenue of $10.0 million as of Q4 2025, which was down 6180.03% from $15.2 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Non-Current Deffered Revenue registered a high of $77.7 million during Q1 2021, and its lowest value of $10.0 million during Q4 2025.
  • Its 5-year average for Non-Current Deffered Revenue is $37.5 million, with a median of $35.2 million in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Non-Current Deffered Revenue tumbled by 7534.66% in 2023 and then soared by 19149.66% in 2024.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Non-Current Deffered Revenue stood at $59.0 million in 2021, then plummeted by 39.05% to $36.0 million in 2022, then grew by 25.15% to $45.0 million in 2023, then tumbled by 41.79% to $26.2 million in 2024, then plummeted by 61.8% to $10.0 million in 2025.
  • Its Non-Current Deffered Revenue was $10.0 million in Q4 2025, compared to $15.2 million in Q3 2025 and $21.6 million in Q2 2025.